Sensus Healthcare, INC Form 4 insider transactions

Sensus Healthcare Director Eric Sachetta acquired 1,500 shares of common stock.

Sensus Healthcare director Eric Sachetta amends prior filing to accurately reflect beneficial ownership of 2,093 shares held indirectly through his spouse.

CFO Javier Rampolla filed an amendment to correct an overstatement of 742 shares in his previously reported beneficial ownership.

Magdalena Martinez, Chief Operating Officer of Sensus Healthcare, Inc., filed an amendment to her beneficial ownership statement, correcting previously reported shareholdings.

Sensus Healthcare Director Eric Sachetta purchased 2,000 shares of common stock at an average price of $3.81, increasing his beneficial ownership.

Sensus Healthcare, Inc. granted 40,000 shares of restricted common stock to Michael Sardano, President and General Counsel, under its 2017 Equity Incentive Plan.

Sensus Healthcare's President and General Counsel, Michael Sardano, filed an amended Form 4 to correct an oversight regarding his spouse's indirect beneficial ownership of 1,000 common shares.

Sensus Healthcare Director Eric Sachetta has reported a planned acquisition of 7,000 shares of common stock at $3.93 per share on November 21, 2025.

Sensus Healthcare, Inc. Director Eric Sachetta acquired 2,500 shares of common stock at $4.50 per share, increasing his total beneficial ownership to 133,113 shares.

Sensus Healthcare CEO Joseph Sardano acquired 25,000 shares of common stock at an average price of $4.03 per share, increasing his beneficial ownership to 1,200,293 shares.

Sensus Healthcare's President and General Counsel, Michael Sardano, purchased 1,000 shares of common stock at $3.80 per share.

President and General Counsel Michael Sardano reported open-market purchases totaling 2,000 SRTS shares on Nov. 11, 2025, including 1,000 directly and 1,000 by his spouse.

Sensus Healthcare's President and General Counsel, Michael Sardano, increased his beneficial ownership of common stock through recent purchases.

Sensus Healthcare's President and General Counsel, Michael Sardano, purchased 1,000 shares of common stock at $4.26 per share on November 11, 2025.

Sensus Healthcare's President and General Counsel, Michael Sardano, purchased 1,000 shares of common stock, increasing his beneficial ownership.

Javier Rampolla, CFO of Sensus Healthcare, purchased 501 shares of common stock at $5.95 per share on February 10, 2025.

Michael Sardano, President and General Counsel of Sensus Healthcare, recently purchased 1,000 shares of the company's common stock.

Sensus Healthcare director Anthony Benedict Petrelli acquired 20,000 shares of restricted stock on December 17, 2024, as part of the company's 2017 Equity Incentive Plan.

Director William H. McCall reports acquisition of 20,000 shares of restricted stock and disposal of 30,000 shares of common stock.

Director Megan Cornish of Sensus Healthcare acquired 20,000 shares of restricted stock, while also disposing of 32,000 shares.

Michael Sardano, President and General Counsel of Sensus Healthcare, acquired 40,000 shares of restricted stock, with a portion vesting immediately and the remainder vesting over three years.

Javier Rampolla, CFO of Sensus Healthcare, reports the disposal of 3,935 common stock shares to cover withholding tax obligations.

Michael Sardano, President and General Counsel of Sensus Healthcare, reports the disposal of 3,935 shares of common stock to cover withholding tax obligations.

William H. McCall, a director at Sensus Healthcare, reports the unauthorized sale of shares held indirectly through Investors Capital Alliance, LLC (ICA).

William H. McCall, a director of Sensus Healthcare, filed an amended Form 4 to correct the number of shares beneficially owned following transactions on May 10, 2022.

William H. McCall, a director of Sensus Healthcare, Inc., filed an amended Form 4 to correct the number of shares beneficially owned following a transaction on July 21, 2021.

Director John Heinrich of Sensus Healthcare, Inc. reports selling a total of 19,990 shares of common stock in two separate transactions on May 17 and May 20, 2024.